Paroxetine (Synonyms: BRL29060)

Name: Paroxetine
Brand: MedChemExpress
SKU: HY-122272
Rating: 5.0 (17 reviews)

Cat. No.: HY-122272 Purity: 99.66% ee.: 97.93%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches.

For research use only. We do not sell to patients.

CAS No. : 61869-08-7

Size	Stock	Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Liquid
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 17 publication(s) in Google Scholar

Other Forms of Paroxetine:

17 Publications Citing Use of MCE Paroxetine

In Vivo Efficacy Study

Cell Proliferation/Viability Assay

RT-PCR

Bio/Physico-chemical Assay

Histological Imaging/Staining

2D/3D Cell Culture and Differentiation

: Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]; IC₅₀ of Paroxetine hydrochloride (1-12.5 μM) in the indicated cell lines.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]; Colony formation assays in the indicated cells treated with DMSO or gradient doses of Paroxetine hydrochloride (0.5-7.5 μM).

: Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]; A375 xenografts were established and treated with vehicle or Paroxetine hydrochloride (25 mg/kg daily intraperitoneally [i.p.]) for 14 days. Tumors in each group were individually recorded every 2 days. n = 8 tumors per group.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]; 5-HT levels in A375 cells treated with DMSO or the indicated Paroxetine hydrochloride treatment for 24 h.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]; A375^DTR xenografts were established and treated with vehicle or PH (25 mg/kg daily i.p. injection) for 15 days. The tumors in each group were individually recorded every 3 days. n = 8 tumors per group.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.; CCK-8 assay was performed with different concentrations of Paroxetine (0.0625-10 μM) in BMMs for 1 day and 3 days.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.; Assessment of mRNA expression levels of osteoclastogenesis-associated marker genes after administration with Paroxetine (0.0625-2.5 μM) by RT-qPCR, including NFATc1, c-fos, RANK, TRAP, Cathepsin K, and MMP9. he results showed that Paroxetine inhibited the expression of NFATc1, c-fos, RANK, TRAP, Cathepsin K, and MMP9 genes in a concentration-dependent manner.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.; Assessment of protein expression levels of NFATc1, c-fos, Cathepsin K and MMP9 after administration with Paroxetine (0.0625-2.5 μM; pretreatment 2 h before stimulation+ 3 d after stimulation) by Western blot. The results demonstrated that, following RANKL stimulation, the protein expression levels of NFATc1, c-fos, CTSK, and MMP9 significantly increased. However, Paroxetine reduced the expression levels of these proteins in osteoclasts in a concentration-dependent manner.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.; Representative fluorescence images of P65 nuclear translocation following RANKL stimulation without or with Paroxetine (PA) (pretreatment 6 h). The results showed that RANKL stimulation led to a significant increase in the mean nuclear fluorescence intensity of p65, whereas Paroxetine treatment attenuated this effect.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.; Histopathology photographs of femoral samples after HE-stained sections. The results revealed that the trabecular bone in the distal femoral region of mice in the LPS group became sparse and thin. In contrast, Paroxetine (PA, 20 mg/kg; i.p.; once daily for 10 days) effectively alleviated bone loss, as evidenced by the intact and well-ordered arrangement of trabeculae in mice of this group.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.; Representative TRAP staining images of RANKL-induced osteoclasts treated with Paroxetine (2.5 μM) on specified days. The results showed that the addition of Paroxetine during the early stage of differentiation (days 1-3) significantly inhibited osteoclast formation. In contrast, when bone marrow-derived macrophages (BMMs) were exposed to Paroxetine from days 3-5 or days 5-7, the number of osteoclasts was also reduced, but the inhibitory effect was less pronounced compared to the early-stage (days 1–3) exposure.

: Paroxetine purchased from MedChemExpress. Usage Cited in: NPJ Digit Med. 2025 Nov 17;8(1):663. [Abstract]; Heat map display of cell viabilities of A549 (Left) and H1299 (Right) cells after incubation with different concentrations of anti-ED compounds (Paroxetine (10–200 μg/mL), et al.) for 48 h. The results showed that paroxetine did not significantly promote tumor cell proliferation; instead, it exerted a mild inhibitory effect on cell growth at higher concentrations.

: Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Apr 2;44(4):115489. [Abstract]; Paroxetine (5 mg/kg; i.p.; once daily for 2–3 weeks) alleviated pain and depression-like symptoms in mice subjected to chronic restraint stress (CRS).

: Paroxetine purchased from MedChemExpress. Usage Cited in: Brain Res. 2019 Oct 1:1720:146296. [Abstract]; Protein levels of IFNα and IRF2(B) are detected in HA1800 Cells at 6 h, 12 h and 24 h after paroxetine (10μM) treatment by RT-qPCR and western blot respectively.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Adrenergic Receptor Isoform Specific Products:

View All Isoforms

α adrenergic receptor β adrenergic receptor

View All P2X Receptor Isoform Specific Products:

View All Isoforms

P2X1 Receptor P2X2 Receptor P2X3 Receptor P2X4 Receptor P2X7 Receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
BTI-TN-5B1-4	IC₅₀	1.38 μM Compound: Paroxetine	Inhibition of full length C-terminal hexahistidine tagged GRK2 (unknown origin) S670A mutant expressed in High Five cells using Bac to Bac insect cell expression system using tubulin as substrate by SDS-PAGE method Inhibition of full length C-terminal hexahistidine tagged GRK2 (unknown origin) S670A mutant expressed in High Five cells using Bac to Bac insect cell expression system using tubulin as substrate by SDS-PAGE method	[PMID: 27050625]
CHO	IC₅₀	0.56 nM Compound: Paroxetine	Inhibition of human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake preincubated for 10 mins followed by [3H]serotonin addition measured after 20 mins by liquid scintillation counting method Inhibition of human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake preincubated for 10 mins followed by [3H]serotonin addition measured after 20 mins by liquid scintillation counting method	[PMID: 27865645]
CHO	IC₅₀	3.9 μM Compound: paroxetine	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
HEK293	IC₅₀	0.2 nM Compound: paroxetine	Displacement of [125I]RTI-55 from human recombinant SERT expressed in HEK293 cells after 1 hr by scintillation counting analysis Displacement of [125I]RTI-55 from human recombinant SERT expressed in HEK293 cells after 1 hr by scintillation counting analysis	[PMID: 23477943]
JAR	IC₅₀	2 nM Compound: 2	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18771916]
MDCK	IC₅₀	100 nM Compound: 2	Inhibition of norepinephrine uptake at human NET expressed in MDCK cells Inhibition of norepinephrine uptake at human NET expressed in MDCK cells	[PMID: 18771916]
U-373MG ATCC	IC₅₀	900 nM Compound: paroxetine	Displacement of [125I]substance P from human recombinant NK1 receptor expressed in human U373 cells after 1 hr by scintillation counting analysis Displacement of [125I]substance P from human recombinant NK1 receptor expressed in human U373 cells after 1 hr by scintillation counting analysis	[PMID: 23477943]
Vero C1008	IC₅₀	7.45 μM Compound: Paroxetine	Antiviral activity against Ebolavirus infected in african green monkey Vero E6 cells assessed as reduction in virus entry after 48 hrs by by Celltiter-Glo luminescent assay Antiviral activity against Ebolavirus infected in african green monkey Vero E6 cells assessed as reduction in virus entry after 48 hrs by by Celltiter-Glo luminescent assay	[PMID: 29272110]

In Vitro

Paroxetine (10-30 μM, 72 h) reduces the viability of MCF-7 cells in a time- and dose-dependent manner^[1].
Paroxetine (10-30 μM, 1-12 h) induces mitochondrial-mediated apoptosis in MCF-7, increasing ROS generation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	MCF-7
Concentration:	0, 10, 30 μM
Incubation Time:	12 h
Result:	Reduced the expression levels of anti-apoptotic proteins Bcl-2 and Bcl-xL, increased the expression level of pro-apoptotic protein Bax, and caused the cleavage of caspase-8 and caspase-9.

Cell Viability Assay^[1]

Cell Line:	MCF-7, MCF-10A
Concentration:	10, 30 μM
Incubation Time:	72 h
Result:	Decreased cell viability.

Apoptosis Analysis^[1]

Cell Line:	MCF-7
Concentration:	30 μM; 10, 30 μM
Incubation Time:	12 h; 1, 3, 6, 12 h
Result:	Led to the translocation of cytochrome C, the expression of cytochrome C in the mitochondria was reduced, and the expression of cytochrome C in the cytoplasm was accumulated. The concentration of reduced glutathione was significantly reduced, and the level of ROS was increased.

In Vivo

Paroxetine (10 mg/kg, intraperitoneally, once a day for 14 days) reduces neurogenic pain in rats both before and after sciatic nerve injury^[2].
Paroxetine (0.3-10 mg/kg, orally, single dose) has anti-anxiety and antidepressant effects in rats, increasing social interaction time^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rat^[2]
Dosage:	10 mg/kg; daily; 14 days
Administration:	Intraperitoneal injection (i.p.)
Result:	Reduced mechanical and thermal hyperalgesia, and also showed effective relief of existing hyperalgesia and thermal hyperalgesia when administration began 7 days after injury.

Animal Model:	Male Sprague-Dawley rats^[3]
Dosage:	0.3, 1, 3, 10 mg/kg; single dose
Administration:	Oral
Result:	Reduced the synthesis rate of serotonin and increased the social time of rats, but had no effect on motor activity. The motor activity of animals taking the drug for a long time was slightly lower than that of animals taking the drug for a short time.

Molecular Weight

329.37

Formula

C₁₉H₂₀FNO₃

CAS No.

61869-08-7

Appearance

Liquid (Density: 1.213±0.06 g/cm³)

Color

Colorless to light yellow

SMILES

FC1=CC=C(C=C1)[C@H]2[C@@H](CNCC2)COC3=CC=C4OCOC4=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (151.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0361 mL	15.1805 mL	30.3610 mL
5 mM	0.6072 mL	3.0361 mL	6.0722 mL
10 mM	0.3036 mL	1.5180 mL	3.0361 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.66% ee.: 97.93%

Select Batch:

Data Sheet (281 KB) SDS (393 KB)

COA (251 KB) HNMR (119 KB) RP-HPLC (86 KB) NP-HPLC (153 KB)

Handling Instructions (2659 KB)

References

[1]. Young-Woo Cho, et al. Paroxetine Induces Apoptosis of Human Breast Cancer MCF-7 Cells through Ca2+-and p38 MAP Kinase-Dependent ROS Generation. Cancers (Basel). 2019 Jan 9;11(1):64. [Content Brief]

[2]. Malek Zarei, et al. Paroxetine attenuates the development and existing pain in a rat model of neurophatic pain. Iran Biomed J. 2014;18(2):94-100. [Content Brief]

[3]. S Lightowler, et al. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav. 1994 Oct;49(2):281-5. [Content Brief]

[4]. M Bourin, et al. Paroxetine: a review. CNS Drug Rev. Spring 2001;7(1):25-47 [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.0361 mL	15.1805 mL	30.3610 mL	75.9025 mL
	5 mM	0.6072 mL	3.0361 mL	6.0722 mL	15.1805 mL
	10 mM	0.3036 mL	1.5180 mL	3.0361 mL	7.5902 mL
	15 mM	0.2024 mL	1.0120 mL	2.0241 mL	5.0602 mL
	20 mM	0.1518 mL	0.7590 mL	1.5180 mL	3.7951 mL
	25 mM	0.1214 mL	0.6072 mL	1.2144 mL	3.0361 mL
	30 mM	0.1012 mL	0.5060 mL	1.0120 mL	2.5301 mL
	40 mM	0.0759 mL	0.3795 mL	0.7590 mL	1.8976 mL
	50 mM	0.0607 mL	0.3036 mL	0.6072 mL	1.5180 mL
	60 mM	0.0506 mL	0.2530 mL	0.5060 mL	1.2650 mL
	80 mM	0.0380 mL	0.1898 mL	0.3795 mL	0.9488 mL
	100 mM	0.0304 mL	0.1518 mL	0.3036 mL	0.7590 mL

Paroxetine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Paroxetine (Synonyms: BRL29060)

Customer Review

Other Forms of Paroxetine:

Paroxetine Related Antibodies

17 Publications Citing Use of MCE Paroxetine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Adrenergic Receptor Isoform Specific Products:

View All P2X Receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Paroxetine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Paroxetine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report